Education
About Us
Working with TipRanks
Follow Us
SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
SOPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.70 - $6.28
Previous CloseN/A
Volume4.05K
Average Volume (3M)67.90K
Market Cap
$217.87M
Enterprise Value$154.47M
Total Cash (Recent Filing)$80.23M
Total Debt (Recent Filing)$30.03M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
May 13, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding66,831,070
10 Day Avg. Volume32,052
30 Day Avg. Volume67,900
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.10
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.52
Enterprise Value/Ebitda-3.00
Forecast
1Y Price Target
$5.67Price Target Upside73.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
SOPHiA GENETICS News
PremiumCompany Announcements
SOPHiA GENETICS Reports 2024 Financial Results
PremiumCompany Announcements
SOPHiA GENETICS Earnings Call: Mixed Results, Optimistic Outlook
PremiumCompany Announcements
SOPHiA GENETICS Reports 2024 Financial Results and Sets Growth Path for 2025
PremiumPre-Earnings
Is SOPH a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Customer Base ExpansionSOPH added 35 new genomics customers to Sophia DDM in Q4, which was solid, partially offset by a ~4% smaller customer churn.
Revenue GrowthSOPH guided for a return to double-digit revenue growth in 2025 as the company is confident in its ability to turn on customers new to SOPH's DDM platform, particularly for the newer MSK-Access liquid biopsy application.
Volume GrowthSOPH reported a total analysis volume of 91K, which was a 16% increase year-over-year, outperforming expectations.
Bears Say
Market DisruptionsThe company faced several headwinds in 2024 resulting in below long-term trend growth, notably from a lower biopharma revenue ramp and disruptions in LATAM.
Revenue DeclineSophia turned in a relatively challenging 2024 as they drove 4% revenue growth while growing their volumes by 11%, which implies a 6-7% decline in revenue per analysis, which declined in part due to headwinds with biopharma customers.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.01% Mutual Funds
19.80% Other Institutional Investors
79.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by SOPHiA GENETICS
Desktop Users
Mobile Users
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $2.70 and its highest was $6.28 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $217.87M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is May 13, 2025 which is in 43 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on Mar 04, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.205 by -$0.025.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.22.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 66,831,070 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.205. Following the earnings report the stock price went down -13.165%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
---
SOPHiA GENETICS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (73.93% Upside)
$5.67 (73.93% Upside)
Blogger Sentiment
Bullish
SOPH Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.87%
12-Months-Change
Fundamentals
Return on Equity
-50.41%
Trailing 12-Months
Asset Growth
-24.13%
Trailing 12-Months
Company Description
SOPHiA GENETICS
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.
---
SOPH Company Deck
---
SOPH Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted several significant achievements, including strong new customer acquisition and improvements in cost management. However, these positives were offset by challenges in the BioPharma sector, a decline in Latin America, and overall flat revenue growth. The company is optimistic about future growth, particularly in the U.S. and with new applications like MSK-ACCESS and MSK-IMPACT.Read More>---
SOPH Stock 12 Month Forecast
Average Price Target
$5.67
▲(73.93% Upside)
Technical Analysis
Best Analysts Covering SOPH
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+13.40%
reiterated a buy rating 15 days ago
Copying Mark Massaro's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +13.40% per trade.
---